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Background
NOD.SCID common gamma chain (NSG) knockout mice
have no functional adaptive immune system of their own
and readily accept human CD34+ hematopoietic stem cell
xenografts (SCID-hu). These SCID-hu represent a unique
opportunity to study human adaptive immunological
responses in a small rodent animal model. We have previ-
ously developed a cell based vaccine system utilizing a
secreted form of heat shock protein gp96 along with HIV
gag protein (293-gp96Ig-HIVgag).
Methods
Day 1 neonatal NSG mice were sub lethally irradiated and
transplanted with 106 human CD34+ hematopoietic stem
cells intrahepatically. The pups were fostered, allowed to
engraft and weened at 28 days. SCID-hu mice were vacci-
nated i.p. with 106 293-gp96Ig-HIVgag cells or 293 cells
on days 0, 14 and 28. On day 33 the mice were sacrificed,
spleen and peritoneal cavity cells (PEC) were harvested. 2
× 105 cells were plated in triplicate, stimulated for 20
hours with 20 μg/ml of SLYNVATL, HIV gag peptide, for
an IFN-γ ELISPOT assay.
Results
Flow cytometry analysis of peripheral blood in pre-vacci-
nation animals revealed human engraftment (mCD45 vs.
hCD45) ranging from 4%–7%. Post vaccination analysis
of the spleen indicated human engraftment ranging from
16–20%, PECs from SCID-hu after gp96 vaccination were
primarily of human origin (90%–95%). SCID-hu vacci-
nated with 293-gp96Ig-HIVgag i.p. generated an HIV spe-
cific immune response. 293-gp96Ig-HIVgag vaccination
generated an average of 778 spots per 2 × 105 cells plated
whereas mice vaccinated with 293 cells alone generated
an average of 88.5 spots per 2 × 105 cells plated (p < 0.05).
Conclusion
We conclude that SCID-hu mice are able to mount a
human HIV-specific immune response after gp96 vaccina-
tion. Given the high cost of nonhuman primate models
SCID-hu further represent an innovative way to study
human immunological responses in a small animal
model.
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